While today’s announcement is exciting, we remain concerned about how long it takes to get medicines funded in New Zealand. The application for lenalidomide for first line treatment was submitted in April 2016; the application for pomalidomide was .
“We are very pleased Pharmac has today announced a Request for Proposal (RFP) for the supply of lenalidomide and pomalidomide to treat multiple myeloma,” says Barbara Horne, Chair of Myeloma New Zealand
“We are very pleased Pharmac has today announced a Request for Proposal (RFP) for the supply of lenalidomide and pomalidomide to treat multiple myeloma,” says Barbara Horne, Chair of Myeloma New Zealand. “While lenalidomide is already available .